Share this article
Share this article
GAITHERSBURG, Md., July 12, 2021 /PRNewswire/ MaxCyte, Inc., (LSE: MXCT) (LSE: MXCN), a leading provider of platform technologies for cell engineering (
MaxCyte or the
Company ), today announced the public filing of a registration statement on Form S-1 with the Securities and Exchange Commission (the SEC ) for a proposed dual-listing and public offering of shares of common stock on the Nasdaq Stock Market (the offering ). The registration statement included a proposed change to the board of directors as well as unaudited financial information which is detailed below.
Financial information in the Form S-1 registration statement
The Company s Form S-1 registration statement contains unaudited consolidated financial statements for the period from 1 January 2021 to 31 March 2021 prepared in accordance with generally accepted accounting principles in the United States ( U.S. GAAP ). Such consolidated financial statements, as extracted
Gaithersburg
Maryland
United-states
London
City-of
United-kingdom
Nick-adams
Duncan-monteith-matthew-odowd
Doug-doerfler
Amanda-murphy
Chris-welsh
Mary-jane-elliott